GenMark Diagnostics (GNMK) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
GenMark Diagnostics (GNMK) Announces Another ePlex Delay; Canaccord Genuity Cuts Price Target to $8
October 28, 2015 11:02 AM EDTCanaccord Genuity maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $8.00 (from $14.00), following the announcement of another delay on ePlex. GNMK cited their need to redesign plastic-injected parts to 2 components of their cartridge. GNMK pushed out its timelines by another quarter,... More
GenMark Diagnostics (GNMK) Pushes ePlex Launch to 2016; Needham & Company Cuts Price Target to $13
October 28, 2015 7:11 AM EDTNeedham & Company maintained a Buy rating on GenMark Diagnostics (NASDAQ: GNMK), and cut the price target to $13.00 (from $16.00), following the company's 3Q15 earnings results. Revenue was $8.5M vs. consensus of $8.2M and GAAP EPS was ($0.27) vs. consensus of ($0.31). Management now believes that the launch of the sample-to-answer... More
